| Bladder and Urothelial Cancer Treatments | Lifetime | 14 | US 11 | 99.83 |
| Radiopharmaceutical Chemistry and Applications | Lifetime | 27 | US 15 | 99.63 |
| Urinary and Genital Oncology Studies | Lifetime | 13 | US 8 | 99.83 |
| Prostate Cancer Treatment and Research | Lifetime | 44 | US 33 | 99.79 |
| Renal cell carcinoma treatment | Lifetime | 40 | US 32 | 99.72 |
| Cancer, Lipids, and Metabolism | Lifetime | 62 | US 35 | 99.66 |
| Multiple and Secondary Primary Cancers | Lifetime | 44 | US 18 | 99.40 |
| Cancer Genomics and Diagnostics | Lifetime | 245 | US 154 | 99.49 |
| Renal and related cancers | Lifetime | 113 | US 73 | 99.28 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 236 | US 137 | 99.42 |
| Cancer Diagnosis and Treatment | Lifetime | 179 | US 96 | 98.82 |
| Prostate Cancer Diagnosis and Treatment | Lifetime | 350 | US 178 | 98.88 |
| Cancer Treatment and Pharmacology | Lifetime | 623 | US 316 | 98.34 |
| Multiple Myeloma Research and Treatments | Lifetime | 435 | US 201 | 97.67 |
| Urological Disorders and Treatments | Lifetime | 675 | US 368 | 97.56 |
| Hormonal and reproductive studies | Lifetime | 606 | US 303 | 97.23 |
| Bone health and treatments | Lifetime | 650 | US 272 | 97.17 |
| Testicular diseases and treatments | Lifetime | 704 | US 282 | 93.83 |
| Economic and Financial Impacts of Cancer | Lifetime | 786 | US 500 | 92.89 |
| Infectious Disease Case Reports and Treatments | Lifetime | 405 | US 199 | 77.23 |
| Bladder and Urothelial Cancer Treatments | 2021-2025 | 28 | US 12 | 99.50 |
| Urinary and Genital Oncology Studies | 2021-2025 | 30 | US 11 | 99.13 |
| Prostate Cancer Treatment and Research | 2021-2025 | 92 | US 40 | 98.93 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 76 | US 25 | 97.50 |
| Radiopharmaceutical Chemistry and Applications | 2021-2025 | 71 | US 24 | 97.91 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 379 | US 151 | 98.55 |
| Renal cell carcinoma treatment | 2021-2025 | 129 | US 54 | 97.63 |
| Multiple and Secondary Primary Cancers | 2021-2025 | 61 | US 24 | 93.12 |
| PARP inhibition in cancer therapy | 2021-2025 | 896 | US 314 | 79.22 |